Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Investor webinar reminder and presentation Highlights:  Shareholders and interested investors are invited to join Neurizon’s investor webinar featuring CEO Dr Chris Bremer and CFO Mr Dan O’Connell  Investor webinar to be held on 5 November 2026 at 1.00pm (Melbourne time) to provide further details on Company’s funding strategy and recent corporate developments 05 November 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to provide the attached investor presentation ahead of its shareholder webinar scheduled for today, Thursday, 5 November 2026. The presentation provides an overview of the Company's recent capital raise, including the $4.3 million placement and proposed $2 million Share Purchase Plan (SPP), alongside the strategic rationale for redeeming the remaining Obsidian convertible notes and strengthening Neurizon's funding position ahead of the anticipated HEALEY ALS Platform Trial topline results in late Q2 CY2027. The presentation also outlines the Company's funding flexibility, ongoing progress, and key development milestones as Neurizon advances NUZ-001 towards its first randomised efficacy readout. Chief Executive Officer, Dr Chris Bremer, and Chief Financial Officer, Dan O'Connell, will host the webinar and provide shareholders with further commentary on the Company's capital management strategy, the SPP and its clinical development priorities. Webinar details:  Date: 5 November 2026  Time: 1:00pm AEDT  Presenters: Dr Chris Bremer, CEO, and Dan O'Connell, CFO  Registration: https://bit.ly/2026CorporateUpdate Shareholders and investors are encouraged to register in advance and submit questions ahead of the webinar. A recording will be made available following the event. -ENDS- This announcement has been authorised for release by Dr Chris Bremer, Chief Executive Officer, on behalf of the Board of Neurizon Therapeutics Limited. For further information, please contact: Marketing & Corporate Affairs Lidija Damjanovic Email: lidija@neurizon.com Phone: +61 (0) 425 700 504 Investor Relations Henry Jordan Email: henry.jordan@sdir.com.au Phone: +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited ABN 35 094 006 023 A strengthened funding position ahead of HEALEY trial topline Shareholder webinar – 5 November 2026 Dr Chris Bremer, Chief Executive Officer Dan O'Connell, Chief Financial Officer 2 Disclaimer This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”). This disclaimer applies to the presentation and all information contained in it. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Future Matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US Disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1933 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. Investor Webinar - November 2026 Our Vision To lead the development of treatments towards a promising new horizon for people living with neurodegenerative diseases. Neurizon: A late clinical-stage biotech developing therapies for neurodegenerative diseases 4 Lead ALS/MND program in Phase 2/3, with topline results expected in late Q2 CY2027 WHO WE ARE Neurizon is developing therapies for neurodegenerative diseases, with its lead investigational therapy, NUZ-001, currently being evaluated in ALS/MND. NUZ-001 is an oral small molecule with preclinical evidence demonstrating effects on cellular protein clearance pathways associated with neurodegeneration. ASX: NUZ · OTCQB: NUZTF LEAD ASSET: NUZ-001 Investigational oral small molecule being developed initially in ALS/MND and currently evaluated in the Phase 2/3 HEALEY ALS Platform Trial. NUZ-001 IN ALS/MND AT A GLANCE ORAL Once-daily administration PHASE 2/3 HEALEY ALS Platform Trial 250 Regimen I participants, randomised 3:1 LATE Q2 2027 Expected topline BUILT AROUND THE CLINICAL OPPORTUNITY CLINICAL VALIDATION 250-participant Phase 2/3 HEALEY API SUPPLY ESTABLISHED Long-term supply agreement with Elanco EXPANDED EVIDENCE NIH-funded EAP up to 200 participants NEAR-TERM CATALYST Topline expected late Q2 CY2027 BROADER POTENTIAL Preclinical evidence in other neurodegenerative diseases Investor Webinar - November 2026 Why look now 5 A randomised Phase 2/3 readout in late Q2 2027 is the next value inflection Late Q2 2027 Expected topline from the 250- participant Phase 2/3 ALS trial. Clinical advancement A 250-participant randomised Phase 2/3 enrolled in less than 5 months – record enrolment for the HEALEY ALS Platform Trial. NIH-funded EAP for NUZ-001. Evidence-led development Promising Phase 1 signals, with an exploratory biomarker panel built into ongoing Phase 2/3 trial. HEALEY provides established clinical infrastructure across 78 US sites led by Mass General Brigham. Supply chain readiness for scale Long-term supply agreement with Elanco for GMP API supply and registration-scale manufacturing. Strategic and commercial optionality An upcoming, randomised Phase 2/3 dataset that will inform Neurizon’s regulatory, partnering and commercial strategy. Total addressable market (TAM) opportunity of ~US$5bn1. 1 3 2 4 NIH-Funded EAP for NUZ-001 for 200 participants up to 96 weeks. 1 Illustrative US TAM of approximately US$5 billion based on projected 2026 US ALS prevalence of approximately 34,720 adults (CDC National ALS Registry) and assumed annual net pricing of US$150,000 per patient. Funding secured Fully funded through to HEALEY topline results. Outstanding convertible notes redeemed. Investor Webinar - November 2026 Placement and Share Purchase Plan (SPP) overview $6.3m in new equity targeted, with the convertible notes now fully redeemed 6 PLACEMENT $4.3m Firm commitments at 6.8c per share from new and existing institutional, sophisticated and professional investors SHARE PURCHASE PLAN Target $2m Eligible shareholders can apply for up to $30,000 at the same 6.8c price, without brokerage OPTIONS 1 for 1 One free option per new share, exercisable at 12c, expiring 18 months from issue (subject to shareholder approval) CONVERTIBLE NOTES ON ISSUE Nil Remaining Obsidian notes redeemed, taking total redemptions to 1,750,000 of 3,575,500 issues. Drawdown resolution withdrawn from AGM ✓ Remain fully funded through to HEALEY topline in late Q2 CY2027 and with no convertible notes held by Obsidian. Funding strategy to topline readout include one further facility drawdown (not before April 2027 and subject to shareholder approval), with the ability to displace it with alternative funding – Multiple avenues are under development and assessment. Investor Webinar - November 2026 Why we acted now Underpinned by clinical and operational momentum 7 WHERE THE PROGRAM IS 1 Fully enrolled with topline pending HEALEY Regimen I: 250 participants in under five months, a record for the platform with topline results remaining on track for late Q2 CY2027 2 Regulatory clarity FDA Type C feedback supports the potential for Regimen I to serve as a single registrational study, subject to substantial evidence of effectiveness 3 Operational readiness Long-term GMP supply agreed with Elanco; NIH-funded Expanded Access Program for ~200 patients in preparation THE OPERATING BACKDROP Capital Structure Simplification The convertible note facility created uncertainty around the Company's capital structure and the potential dilution. Removing the notes from the structure removes this uncertainty. The opportunity A 56% share price recovery from 1 September to 28 October 2026 following a standstill with Obsidian1. Neurizon performed strongly against peer group over both short and long term (3, 6 and 12 months)2 Market Positioning With a fully enrolled potentially registrational trial that will read out in late Q2 CY2027, Neurizon is very well positioned. The simplified capital structure and the reduced selling should allow better recognition of this. 1 1 September 2026 was the last day of selling by Obsidian prior to the agreed standstill between Obsidian and Neurizon. 2 Source: ASX closing prices; company analysis. Peers: Prescient, Alterity, Amplia, Noxopharm, Race Oncology, Arovella, Dimerix and Imugene. Investor Webinar - November 2026 SPP rationale and overview Acting in the best interest of shareholders 8 1 Outstanding Obsidian notes redeemed All remaining notes redeemed for cash: 1,750,000 in total have been bought back rather than converted, so no conversion shares can be issued 2 Equal opportunity for participation The SPP offers the same 6.8c price and the same 1 for 1 options, up to $30,000 per holder, without brokerage 3 Continued engagement with our shareholders The AGM drawdown resolution is withdrawn. Any future drawdown needs shareholder approval, after the Board has considered all alternatives 4 Board and management alignment Directors, management and their direct networks have contributed strongly to this raise. SPP offer metrics: 20.9% discount to last close of 8.6c (28 October 2026) 18.9% discount to the 5-day VWAP of ~8.38c 6.8c in line with the 3-month VWAP (6.80c) and above the 6-month VWAP (6.70c) Investor Webinar - November 2026 Indicative timetable 9 Event Dates (Melbourne time) SPP record date 7.00pm, Friday, 30 October 2026 Announce results of Placement, announce SPP, trading halt lifted and return to trading on the ASX Pre-market Monday, 2 November 2026 Settlement of New Shares under the Placement2 Friday, 6 November 2026 Allotment date and expected normal trading of New Shares under the Placement2 Monday, 9 November 2026 SPP opening date and New Options offer opening date Monday, 16 November 2026 Annual General Meeting Wednesday, 25 November 2026 SPP closing date 5.00pm, Friday, 4 December 2026 Results of SPP announced Friday, 11 December 2026 Issue of New Shares under SPP Friday, 11 December 2026 New Shares under SPP commence trading on ASX Monday, 14 December 2026 Despatch of holding statements in respect of SPP New Shares Tuesday, 15 December 2026 General Meeting to approve Director Participation and the New Options Thursday, 17 December 2026 Issue of New Shares under Director Participation and issue of New Options under Placement and SPP3 Late-December 2026 Expected normal trading of New Shares under Director Participation and New Options under Placement and SPP3 Late-December 2026 1. The above timetable is indicative only and the Company reserves the right to withdraw the Placement or vary the timetable for the Placement at any time before the issue of the relevant securities without notice, subject to the Listing Rules and the Corporations Act and other applicable laws. The Company reserves the right to close the SPP early, extend the SPP closing date or to withdraw the SPP, in its sole and absolute discretion, by lodging an announcement with the ASX. The commencement of trading and quotation of New Shares and New Options is subject to ASX confirmation. The Company gives no assurance that such quotation will be granted. 2. Excluding New Shares to be issued to Directors as subject to shareholder approval at the General Meeting. 3. Subject to shareholder approval being obtained at the General Meeting and quotation condition being satisfied (as applicable). Investor Webinar - November 2026 Near term value catalysts 10 Multiple workstreams underway to drive shareholder value Investor Webinar - November 2026 Area Development Indicative timing Preclinical Further Preclinical Insights into Mechanism of Action of NUZ-001 Mid Q4 CY2026 Clinical First HEALEY Regimen I participant completes Randomised Treatment phase and enters A ctive Treatment Extension Mid Q4 CY2026 Corporate Quarterly R&D Funding acceleration (Dare Strategic Loan Facility) Mid Q4 CY2026 Corporate AGM & AGM Presentation Mid Q4 CY2026 Corporate SAB and KOL formation Late Q4 CY2026 Corporate FY2026 R&D Tax rebate – refund from Australian Taxation Office Late Q4 CY2026 Corporate Presentation at International Symposium on MND/ALS Late Q4 CY2026 Clinical First EAP participant enrolled Mid Q1 CY2027 CMC First boundary batch manufactured Q1 CY2027 Regulatory FDA Type D Meeting Q1 CY2027 Clinical, corporate, regulatory and scientific workstreams underway to unlock shareholder value and further strengthen readiness. A roadmap to topline readout and beyond Multiple material developments converging over the coming quarters Q4 CY2026 Expanding Pre-Clinical Evidence Addressing MOA questions CY2027 Expanded Access opens Adds long-term safety and real-world data in a broader population Q2 CY2027 Trial completion and database lock Final step before unblinding Late Q2 CY2027 HEALEY topline First randomised efficacy data: the defining event Post-topline Regulatory engagement on the data Sets the route and timing to market Timing reflects current company guidance and planning, and may change. EMA advice and Expanded Access timing to be confirmed by management before external use. 11 Investor Webinar - November 2026 Investment summary 12 A defining randomised readout in late Q2 CY2027, with groundwork in place Late Q2 CY2027 HEALEY Regimen I topline: the first randomised efficacy data for NUZ-001. 1 A 250-participant randomised Phase 2/3 in ALS, efficiently run 2 Record enrolment within the HEALEY platform, in under five months 3 Early clinical signals that shaped the Phase 2/3 trial design 4 Supply, manufacturing and biomarker work already in place 5 Established regulatory foundations with partnering and commercial optionality Investor Webinar - November 2026 Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com Thank You